NEW YORK, NY / ACCESSWIRE / October 10, 2018 / U.S. equities finished mostly lower on Tuesday as interest rate increases and rising bond yields continued to put pressure on stocks. The Dow Jones Industrial Average declined 0.21 percent to close at 26,430.57, while the S&P 500 Index decreased 0.14 percent to close at 2,880.34. The Nasdaq Composite Index closed up 0.03 percent to close at 7,738.02, fueled by gains in tech shares.
“We continue to believe the curve should flatten as the Fed continues on their tightening path and see real money demand for the long-end offsetting higher supply. On balance, the risks to our forecasts are skewed toward higher rate levels and a flatter curve, though it may take a further improvement in productivity or global growth to shift rates materially upward,” said Mark Cabana, a rates strategist at Bank of America Merrill Lynch.
RDI Initiates Coverage on:
Arbutus Biopharma Corporation
https://rdinvesting.com/news/?ticker=ABUS
Akcea Therapeutics, Inc.
https://rdinvesting.com/news/?ticker=AKCA
Arbutus Biopharma's stock moved 33.99% lower Tuesday, to close the day at $6.00. The stock recorded a trading volume of 3,772,699 shares, which was above its three months average volume of 427,813 shares. In the last year, Arbutus Biopharma's shares have traded in a range of 4.30 - 12.60. The share price has gained 39.53% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $9.53 is above its 200-day moving average of $7.89. Shares of Arbutus Biopharma have fallen roughly 44.44 percent in the past month and are up 18.81 percent year-to-date.
Access RDI's Arbutus Biopharma Corporation Research Report at:
https://rdinvesting.com/news/?ticker=ABUS
On Tuesday, shares of Akcea Therapeutics recorded a trading volume of 545,150 shares, which was above the three months average volume of 327,429 shares. The stock ended the day 4.95% higher at $29.91. The share price has fallen 26.6% from its 52 week high with a 52 week trading range of 15.20 - 40.75. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $29.53 is above its 200-day moving average of $27.27. Shares of Akcea Therapeutics have gained roughly 14.29 percent in the past month and are up 72.29 percent year-to-date.
Access RDI's Akcea Therapeutics, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=AKCA
Our Actionable Research on Arbutus Biopharma Corporation (NASDAQ:ABUS) and Akcea Therapeutics, Inc. (NASDAQ:AKCA) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani,
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com